Malignant Lymphomas in Immunocompromised Hosts, in Particular with AIDS

  • Umberto Tirelli
  • Emanuela Vaccher
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


Prior to the AIDS epidemic, malignant lymphomas, in particular non-Hodgkin’s lymphoma (NHL), were described in up to 30% of the patients with primary immunodeficiency disorders such as the X-linked lymphoproliferative syndrome or the Wiscott Aldrich syndrome. Moreover, patients with immune deficiency secondary to cytostatic anticancer therapy and also following organ transplantation, autoimmune diseases and connective tissue disorders are at increased risk of NHL The lymphomas which arise in all these settings and in patients with HIV infection have certain features in common, including 1) prevalence of high-grade pathological types, predominantly large cell and immunoblastic lymphomas, or small non-cleaved cell; 2) restriction to B-cell origin; 3) widely disseminated disease at presentation; 4) poor prognosis compared to patients with “common” lymphomas.


Opportunistic Infection Malignant Lymphoma Primary Central Nervous System Lymphoma Pneumocystis Carinii Pneumonia Central Nervous System Relapse 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ziegler JL, Beckstead JA, Volberding PA et al: Non-Hodgkin lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome. N Engl J Med 1984 (311):565–570PubMedCrossRefGoogle Scholar
  2. 2.
    Knowles DM, Chamulak GA, Subar M et al: Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1987). Ann Intern Med 1988 (108): 744–753PubMedGoogle Scholar
  3. 3.
    Lowenthal DA, Straus DJ, Campbell SW et al: AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 1988 (61):2325–2337PubMedCrossRefGoogle Scholar
  4. 4.
    Kaplan LD, Abrams Dl, Feigal E et al: AIDS-asso-ciated non-Hodgkin’s lymphoma in San Francisco. JAMA 1989 (261):719–724PubMedCrossRefGoogle Scholar
  5. 5.
    Roithmann S, Toledano M, Tourani JM et al: HIV-associated non-Hodgkin’s lymphomas: clinical characteristics and outcome. The experience of the French Registry of HIV-associated tumors. Ann Oncol 1991 (2):289–295PubMedGoogle Scholar
  6. 6.
    Levine AM, Sullivan-Halley J, Pike MC et al: Human immunodeficiency virus-related lymphoma - prognostic factors predictive of survival. Cancer 1991 (68):2466–2472PubMedCrossRefGoogle Scholar
  7. 7.
    Pedersen C, Gerstoft J, Lundgren JD et al: HIV-associated lymphoma - histopathology and association with Epstein-Barr virus genome related to clinical, immunological and prognostic features. Eur J Cancer 1991 (27):1416–1423PubMedCrossRefGoogle Scholar
  8. 8.
    Gill P, Levine A, Krailo M et al: AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987 (5): 1322–1328PubMedGoogle Scholar
  9. 9.
    Monfardini S, Tirelli U, Vaccher E et al: Malignant lymphomas in patients with or at risk for AIDS. JNCI 1988 (80):855–860Google Scholar
  10. 10.
    Levine AM, Wernz JC, Kaplan L et al: Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective, multi-institutional trial. JAMA 1991 (266):84–88PubMedCrossRefGoogle Scholar
  11. 11.
    Levine A: Epidemiology, clinical characteristics and management of AIDS-related lymphoma. Hemat/ Onc Clin of North Amer 1991 (2):331Google Scholar
  12. 12.
    Pluda J, Broder S, Yarchoan R: Therapy of AIDS and AIDS-associated neoplasms. In: Pinedo HM, Longo DL and Chabner BA (eds) Cancer Chemotherapy and Biological Response Modifiers Annual 13. Elsevier Science Publishers BV, Amsterdam 1992 pp 395–439Google Scholar
  13. 13.
    Northfelt D and Kaplan LD: Clinical aspects of AIDS-related non-Hodgkin’s lymphoma. Curr Opin Oncol 1991 (3):872–880PubMedCrossRefGoogle Scholar
  14. 14.
    Boyle M, Swanson CE, Turner JJ et al: Definition of two distinct types of AIDS-associated non-Hodgkin lymphoma. Br J Haem 1990 (76):506–512CrossRefGoogle Scholar
  15. 15.
    Biggar RJ, Horm J, Goedert JJ, Melbye M: Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 1987 (126):578–586PubMedGoogle Scholar
  16. 16.
    Goldstein J, Dickson DW, Moser FG et al: Primary central nervous system lymphoma in acquired immune deficiency syndrome. Cancer 1991 (67): 2756–2765PubMedCrossRefGoogle Scholar
  17. 17.
    Ziegler JL: “Biologic” differences in acquired immune deficiency syndrome-associated non-Hodgkin’s lymphomas? J Clin Oncol 1991 (8): 1329–1331Google Scholar
  18. 18.
    Kalter SP, Riggs SA, Cabanillas F et al: Aggressive non-Hodgkin’s lymphomas in immunocompromised homosexual males. Blood 1985 (3):655–659Google Scholar
  19. 19.
    Bermudez MA, Grant KM, Rodvien R, Mendes F: Non-Hodgkin’s lymphoma in a population with or at risk for acquired immunodeficiency syndrome: Indication for intensive chemotherapy. Am J Med 1989 (86):71–76PubMedCrossRefGoogle Scholar
  20. 20.
    Monfardini S, Vaccher E, Foà R, Tirelli U: AIDS-associated non-Hodgkin’s lymphoma in Italy: intravenous drug users versus homosexual men. Ann Oncol 1990 (1):203–211PubMedGoogle Scholar
  21. 21.
    Sawka CA, Shepherd FA, Brandwein J, Burkers RL, Sutton D, Warner E: Treatment of AIDS-related non-Hodgkin’s lymphoma with a twelve week chemotherapy program. Leukemia and Lymphoma 1992 (8):213–220PubMedCrossRefGoogle Scholar
  22. 22.
    Matsushima Y, Kanzawa F, Hoshi A: Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985 (14):104–107PubMedCrossRefGoogle Scholar
  23. 23.
    Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES: Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus and human T-cell leukemia virus type I-related non-Hodgkin’s lymphoma: a highly active regimen. Blood 1993 (10):2810–2815Google Scholar
  24. 24.
    Taillan B, Garnier G, Ferrari E et al: MACOP-B chemotherapy for the treatment of high-grade lymphomas in patients with HIV-1 infection. Acta Haematol 1993 (89): 10–12PubMedCrossRefGoogle Scholar
  25. 25.
    Lopez TM, Hagemeister FB, McLaughlin P et al: Small noncleaved cell lymphoma in adults: superior results for stages l-lll disease. J Clin Oncol 1990 (4):615–622Google Scholar
  26. 26.
    Straus DJ, Wong GY, Liu J et al: Small non-cleaved-cell lymphoma (undifferentiated lymphoma, Burkitt’s type) in American adults: results with treatment designed for acute lymphoblastic leukemia. Am J Med 1991 (90):328PubMedGoogle Scholar
  27. 27.
    Coiffier B, Gisselbrecht C, Herbrecht R et al: LNH-84: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989 (7):1018–1026PubMedGoogle Scholar
  28. 28.
    Gisselbrecht C, Oksenhendler E, Tirelli U et al: Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. Am J Med 1993 (95): 188–196PubMedCrossRefGoogle Scholar
  29. 29.
    Tirelli U, Errante D, Oksenhendler E et al: Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poorprognosis AIDS-related non-Hodgkin’s lymphoma. Ann Oncol 1992 (3):843–847PubMedGoogle Scholar
  30. 30.
    Huhn D, Weiss R, Nerl C et al: HIV-related non-Hodgkin’s lymphoma: CHOP-induction and AZT/IFa-maintenance therapy. Proc ASCO 1993 (12):52 (abstract #12)Google Scholar
  31. 31.
    Levine AM, Katz-Willson E, Espina B et al: Low dose m-BACOD with concomitant dideoxyctidine (ddC) in AIDS related lymphoma. Blood 1992 (80/1 suppl 1): 328a (abstract #1301)Google Scholar
  32. 32.
    Kaplan LD, Kahn JO, Crowe S et al: Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J Clin Oncol 1991 (6):929–940Google Scholar
  33. 33.
    Walsh C, Wernz JC, Levine A et al: Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin’s lymphoma. JAIDS 1993 (6):265–271Google Scholar
  34. 34.
    Hahn SM, Pluda J, Shay L et al: Treatment of AIDS-related non-Hodgkin’s lymphoma (NHL) with chemotherapy, AZT, and granulocyte-macrophage colony-stimulating factor (GM-CSF). VII International Conference on AIDS, Florence 16–21 June, 1991, p 274 (abstract WB 2368)Google Scholar
  35. 35.
    Tirelli U, Errante D, Vaccher E et al: Treatment of HIV-related non-Hodgkin’s lymphoma (NHL) with chemotherapy (CT) and G-CSF: reduction of hospitalization and toxicity with concomitant overall reduction in the cost. Proc ASCO 1993 (12):53 (abstract # 13)Google Scholar
  36. 36.
    Formenti SC, Gill PS, Lean E et al: Primary central nervous system lymphoma in AIDS: results of radiation therapy. Cancer 1989 (63):1101–1107PubMedCrossRefGoogle Scholar
  37. 37.
    Baumgartner JE, Rachlin JR, Beckstead JH et al: Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990 (73):206–211PubMedCrossRefGoogle Scholar
  38. 38.
    Remick SC, McSharry JJ, Wolf BC et al: Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin’s lymphoma. J Clin Oncol 1993 (9):1691–1702Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Umberto Tirelli
    • 1
  • Emanuela Vaccher
    • 1
  1. 1.Division of Medical Oncology and AIDSCentro di Riferimento OncologicoItaly

Personalised recommendations